Ligand Pharmaceuticals Incorporated (LGND) Stock Overview
Explore Ligand Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Ligand Pharmaceuticals Incorporated (LGND)
Key Financials
Key Financials
Market Cap
6.3B
P/E Ratio
31.25
EPS (TTM)
$9.11
ROE
0.20%
LGND Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Ligand Pharmaceuticals Incorporated's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of LGND on the NASDAQ shows an RSI of 70.59, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $205.70 for the NASDAQ listing.
Key metrics behind Ligand Pharmaceuticals Incorporated's NASDAQ-traded stock include a P/E ratio of 31.25 and a market capitalization of 6.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of LGND on the NASDAQ.